<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Microsomal <z:chebi fb="0" ids="17855">triglyceride</z:chebi> transfer protein (MTP) takes part in the mobilization of <z:chebi fb="0" ids="17855">triglyceride</z:chebi>-rich <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> from enterocytes and hepatocytes </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the effects of JTT-130, a novel intestine-specific MTP inhibitor, on impaired <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism in <z:chebi fb="3" ids="16646">Zucker</z:chebi> diabetic fatty (ZDF) rats </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Male ZDF rats were fed a regular powdered diet with or without JTT-130 as a food admixture (0.01-0.02%) for 6 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Food intake, body weight, blood biochemical parameters, fecal <z:chebi fb="23" ids="18059">lipid</z:chebi> contents, hepatic <z:chebi fb="23" ids="18059">lipid</z:chebi> contents, tissue <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels and <z:chebi fb="105" ids="17234">glucose</z:chebi> utilization in adipose tissues were assessed </plain></SENT>
<SENT sid="4" pm="."><plain>An intraperitoneal <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test (IPGTT) and histological analysis of the pancreas were performed </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: JTT-130 treatment decreased food intake, glycated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, plasma levels of <z:chebi fb="105" ids="17234">glucose</z:chebi>, <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and total cholesterol, hepatic levels of <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and cholesterol and hepatic <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of <z:chebi fb="105" ids="17234">glucose</z:chebi>-6-phosphatase, <z:chebi fb="0" ids="18021">phosphoenolpyruvate</z:chebi> carboxykinase and <z:chebi fb="15" ids="28757">fructose</z:chebi>-1,6-bisphosphatase </plain></SENT>
<SENT sid="6" pm="."><plain>JTT-130 treatment increased fecal levels of free fatty acids and cholesterol, plasma levels of glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 and <z:chebi fb="7" ids="16670">peptide</z:chebi> YY, <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of <z:chebi fb="105" ids="17234">glucose</z:chebi> transporter 4 (GLUT4) and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> lipase in adipose tissues and GLUT4 in muscle and <z:chebi fb="105" ids="17234">glucose</z:chebi> utilization in adipose tissues </plain></SENT>
<SENT sid="7" pm="."><plain>Plasma insulin decreased after 2 weeks and increased after 4 weeks of JTT-130 treatment </plain></SENT>
<SENT sid="8" pm="."><plain>Plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> in the JTT-130-treated rats was lower with higher plasma insulin than in the control rats during the IPGTT </plain></SENT>
<SENT sid="9" pm="."><plain>The islets of the JTT-130-treated rats were larger and contained more insulin than those of the control rats </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: JTT-130 ameliorates impaired <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism in the ZDF rats thereby suggesting that JTT-130 could be useful for prevention and treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>